natgillin/translations-raw huggingface dataset:
Interupt pazopanib until transaminases return to Grade 1 or baseline.
Prekinite zdravljenje s pazopanibom, dokler se aminotransferaze ne vrnejo na stopnjo 1 ali izhodiščno vrednost.
interval > 500 ms (see section 4.8).
> 500 ms (glejte poglavje 4.8).
intervals will be required.
imunosupresiva.
Intervention- free survival in this pivotal population (defined as survival without the requirement for long-term (3 month) re-introduction of PEG-ADA, or stem cell transplant) was 92% (11/12 subjects) (82% (14/17 subjects) for integrated population).
V tej ključni populaciji je bilo preživetje brez ukrepanja (opredeljeno kot preživetje brez potrebe po dolgotrajni ( 3-mesečni) ponovni uvedbi PEG-ADA in brez potrebe po presaditvi matičnih celic) 92 % (11/12 bolnikov) (82 % (14/17 bolnikov) za skupno populacijo).
Intervertebral disc protrusion (NB), Jaw pain (NB), Groin pain (N)
protruzija intervertebralnega diskusa (NB), bolečina v čeljusti (NB), bolečina v dimljah (N)
Intervet de Bilt Ambachtstraat 2, De Bilt The Netherlands
Intervet de Bilt Ambachtstraat 2, De Bilt Nizozemska
Intervet International B. V. Wim de Körverstraat 35 5831 AN Boxmeer
Intervet International B. V.
Intervet International B.V. NL - 5831 AN Boxmeer
Intervet International B.V. NL – 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer Nizozemska
Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer Nizuozemska
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer Nizozemska
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 NL – 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer The Netherlands
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer NIzozemska
Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer
Intervet International BV Wim de Körverstraat 35 NL-5831 AN Boxmeer Nizozemska
Intervet International BV, site De Bilt Ambachtstraat 4
Intervet International IBV, site De Bilt Ambachtstratt 4
Intervet Productions SA Rue de Lyons
Intervet Productions S.A. Rue de Lyons
intestinal
in perforacije prebavil)
intestinal
prebavil (ulkusi
Intestinal
črevesna
intestinal bacterial infection; urinary tract infection
črevesna bakterijska okužba, okužba sečil
Intestinal blockage
zaprtje črevesa
Intestinal blockage
zaprtje črevesa,
Intestinal blockage;
zaprtje črevesa,
Intestinal disorders
Bolezni živčevja
Intestinal haemorrage (bleeding in the gut)
intestinalna hemoragija (krvavitev v prebavila)
Intestinal haemorrhage
krvavitev v prebavilih
intestinal infections (including gastroenteritis viral),
črevesne okužbe (vključno z virusnim gastroenteritisom),
Intestinal obstruction
Intestinalna obstrukcija
Intestinal obstruction
Zapora črevesa
Intestinal obstruction
črevesna zapora
intestinal obstruction (blockage in intestine)
zapora črevesa (blokada v črevesu)
Intestinal obstruction (blockage of the bowel).
Obstrukcija črevesa (zapora črevesa).
Intestinal obstruction (in abdominal surgeries)
obstrukcija črevesja (pri abdominalnih operacijah)
Intestinal obstruction*
zapora črevesja
Intestinal obstruction,
črevesna
Intestinal obstruction, Ascites, Enteritis, Gastritis, Dysphagia, Abdominal pain lower, Oesophagitis, Abdominal discomfort, Gastrooesophageal reflux disease, Colitis, Blood in stool
črevesna obstrukcija, ascites, enteritis, gastritis, disfagija, bolečina v spodnjem delu trebuha, ezofagitis, nelagodje v trebuhu, gastroezofagealna refluksna bolezen, kolitis, kri v blatu
intestinal obstruction, ileus
zapora črevesa, ileus
Intestinal obstruction, ileus/subileus, intestinal perforation
obstrukcija črevesja, ileus/subileus in perforacija črevesja
Intestinal obstruction, Recto-vaginal fistulaed,e, Gastrointestinal Disorder, Proctalgia
Prirojene in dedne genetske okvare
intestinal perforation (hole in the intestine)
intestinalna perforacija (predrtje črevesa)
Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn’s disease, and ulcerative colitis and toxic megacolon/megarectum.
Perforacija ali obstrukcija črevesa zaradi strukturne ali funkcijske okvare črevesne stene, obstruktivni ileus, huda vnetna stanja črevesa, kot so Crohnova bolezen, ulcerativni kolitis in toksični megakolon/megarektum.
Intestinal perforation Peritonitis
perforacija črevesa peritonitis hipestezija ustne sluznice parestezija ustne sluznice
intestinal perforation;
intestinalna perforacija;
intestinal stenosis, colitis, enteritis, oesophagitis
intestinalna stenoza, kolitis, entreitis, ezofagitis
Intestinal transplantation
Presaditev črevesa
Intestinal ulceration
Razjede v prebavilih
Intestinal ulcers
razjede v črevesju
Intestinala/duodenal perforation
perforacija črevesaa/dvanajstnika
Intestines
črevesje
into a muscle
v mišicah
into the uterus or from the vagina
krvavitvami v maternici ali iz nožnice
Intolerance
Intoleranca
Intolerance to alcohol
neprenašanje alkohola,
Intolerance to excipients
Neprenašanje pomožnih snovi
intolerance, feeling jittery, infusion site pain, infusion site
bolečine na mestu infundiranja, flebitis na mestu infundiranja,
Intolerant
Ne prenašajo
Intolerant (n=95)
neprena- šanje (n=95)
Intolerant without MCyR
neprenašanje brez pomembnega
Intra-abdominal
Intraabdominalno
Intra-abdominal haemorrhage
intraabdominalne krvavitve
Intra-abdominal infections
okužb v trebušni votlini,
Intra-and interindividual variation in pharmacokinetic characteristics of stavudine is low, approximately 15% and 25%, respectively, after oral administration.
Intra- in interindividualne razlike v farmakokinetičnih značilnostih stavudina po peroralni uporabi so majhne (približno 15% intra- in 25% interindividualno).
Intra-articular haemorrhage
znotrajsklepna krvavitev
Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7- fold human exposure based on Cmax).
Pri psih so opažali upočasnjeno prevajanje impulzov v srcu, pri tem je bil odmerek brez učinka 15 mg/kg (kar pomeni izpostavljenost, ki je 7-krat večja od izpostavljenosti pri človeku glede na Cmax).
Intra-thoracic
Intratorakalno
Intraabdominal Infections (IAI)
Okužbe v trebuhu (Intraabdominal Infections - IAI)
Intraarterial use
Intraarterijska uporaba
Intracellular ara-GTP Cmax and AUC(0–t) values at the same dose level were 2– to 3– fold greater on average in adult female than in adult male patients.
Pri istem odmerku so bile znotrajcelične vrednosti Cmax in AUC(0–t) ara-GTP pri odraslih bolnicah v povprečju za 2- do 3-krat večje kot pri odraslih bolnikih.
Intracellular cGMP causes secretion of chloride and bicarbonate into the intestinal lumen, through activation of the cystic fibrosis transmembrane conductance regulator (CFTR), which results in increased intestinal fluid and accelerated transit.
Znotrajcelični cGMP povzroči izločanje klorida in hidrogenkarbonata v črevesno svetlino z aktiviranjem transmembranskega regulatorja cistične fibroze (CFTR – cystic fibrosis transmembrane conductance regulator), kar poveča količino črevesne tekočine in pospeši prehod.
Intracellular pharmacokinetics: In a clinical study, the intracellular half-life of emtricitabine-triphosphate in peripheral blood mononuclear cells was 39 hours.
Znotrajcelične farmakokinetične lastnosti: V kliničnih študijah je bila znotrajcelična razpolovna doba emtricitabin-trifosfata v perifernih mononuklearnih krvnih celicah 39 ur.
Intracellularly, cytarabine is converted into cytarabine-5’-triphosphate (ara-CTP), which is the active metabolite.
Znotraj celic se citarabin pretvori v aktivni presnovek, citarabin-5’- trifosfat (ara-CTP).
Intracerebral bleeding
Znotrajmožganska krvavitev
Intracranial
Intrakranialne
Intracranial
n = 2.780
Intracranial bleeding
intrakranialna krvavitev
Intracranial bleeding (some
krvavitev v
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness
Intrakranialna krvavitev (opisani so primeri s smrtnim izidom), glavobol, parestezija, omotica
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness
intrakranialna krvavitev (opisani so primeri s smrtnim izidom), glavobol, parestezije, omotica
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness
krvavitev (opisani so primeri s smrtnim izidom), glavobol, parestezije, omotica
Intracranial bleeding was reported in 1% of patients exposed to Jakavi and 0.9% exposed to reference treatments.
O intrakranialni krvavitvi so poročali pri 1 % bolnikov, ki so prejemali zdravilo Jakavi, in pri 0,9 % tistih, ki so prejemali primerjalno zdravilo.
Intracranial bleeding: Spontaneous ICHs were reported in similar rates for ticagrelor 60 mg and ASA therapy alone (n=13, 0.2% in both treatment groups).
Intrakranialna krvavitev: Spontane intrakranialne krvavitve so opažali v podobnih deležih med uporabo 60 mg ticagrelorja in med uporabo same ASA (n = 13, 0,2 % v obeh terapevtskih skupinah).
Intracranial bleeding: There were more intracranial non-procedural bleeds with ticagrelor (n=27 bleeds in 26 patients, 0.3%) than with clopidogrel (n=14 bleeds, 0.2%), of which 11 bleeds with ticagrelor and 1 with clopidogrel were fatal.
Intrakranialna krvavitev: S ticagrelorjem je bilo več intrakranialnih krvavitev, nepovezanih s postopki (n = 27 krvavitev pri 26 bolnikih, 0,3 %) kot s klopidogrelom (n = 14 krvavitev, 0,2 %); od teh je bilo smrtnih 11 krvavitev s ticagrelorjem in 1 s klopidogrelom.
Intracranial Disease Control Rate (IC-DCR) at 12 weeks was 65% and 46% for crizotinib and chemotherapy-treated patients, respectively.
Delež nadzora intrakranialne bolezni (IC-DCR – Intracranial Disease Control Rate) po 12 tednih je bil 65 % v skupini s krizotinibom in 46 % v skupini s kemoterapijo.
Intracranial haemorrhage
možganska krvavitev
Intracranial haemorrhage
znotrajlobanjska krvavitev
Intracranial haemorrhage (ICH)
intrakranialna krvavitev (ICH)
Intracranial haemorrhage (such as cerebral haemorrhage, cerebral haematoma, haemorrhagic stroke, haemorrhagic transformation stroke, intracranial haematoma, subarachnoid haemorrhage) including associated symptoms as somnolence, aphasia, hemiparesis, convulsion
intrakranialna krvavitev (na primer možganska krvavitev, možganski hematom, hemoragična možganska kap, hemoragična transformacija kapi, intrakranialni hematom, subarahnoidna krvavitev), tudi povezani simptomi, kot so zaspanost, afazija, hemipareza, konvulzija
Intracranial haemorrhage after protocol
Intrakranialna krvavitev po spremembi
Intracranial haemorrhage Cerebrovascular accident
intrakranialna krvavitev cerebrovaskularni inzult
Intracranial haemorrhage occurred at a rate of 0.93% vs.
Pogostnost možganskih krvavitev je bila 0,93 % med zdravljenjem s tenekteplazo in 0,94 % med zdravljenjem z alteplazo.
intracranial haemorrhage*
intrakranialna krvavitev
intracranial haemorrhage*, syncope, somnolence, lethargy
intrakranialna krvavitev*, sinkopa, somnolenca, letargija
Intracranial hypertension (IH) with papilloedema, visual changes, headache, nausea and/or vomiting has been reported in patients treated with INCRELEX, as has been reported with therapeutic GH administration.
Pri bolnikih, ki so se zdravili z zdravilom INCRELEX, so poročali o intrakranialni hipertenziji (IH) s papiledemom, motnjami vida, glavoboli, navzeo in/ali bruhanjem, podobno kot pri zdravljenju z GH.
Intracranial hypertension/increased intracranial pressure
Intrakranialna hipertenzija/zvišan intrakranialni tlak
intracranial neoplasm, arteriovenous malformation or aneurysm
intrakranialni tumor, arteriovenska malformacija ali anevrizma,
Intracranial pressure increased
povišan tlak v lobanji,
Intracranial pressure increased (papilloedema, fontanelle bulging), paraesthesia
povišan intrakranialni tlak (papiloedem, nabreklost fontanel), parestezija
Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.
Pri bolnikih, ki so se pri prvem tumorju zdravili z obsevanjem glave, je bil intrakranialni tumor, še posebej meningiom, najpogostejša druga novotvorba.
Intracranial, n
Intrakranialne, n
Intradermal 15µg
Intradermalno 15 µg
Intradermal use
Intradermalna uporaba
Intradermal use
Intradermalna uporaba.
Intradermal use, Intratumoral use, Peritumoral use, Subcutaneous use
Intradermalna, subkutana, intratumoralna, peritumorna uporaba
Intradermal, subcutaneous, intratumoural, or peritumoural use after radiolabelling with sodium pertechnetate (99mTc).
Intradermalna, subkutana, intratumoralna ali peritumorna uporaba po radiooznačevanju z natrijevim pertehnetatom (99mTc).
Intradermal, subcutaneous, intratumoural, or peritumoural use.
Intradermalna, subkutana, intratumoralna ali peritumorna uporaba.
Intrahepatic cholestasis, jaundice
intrahepatična holestaza, ikterus
Intrahepatic cholestasish, jaundicea,h
intrahepatična holestazah, ikterusa,h
Intralesional use
Intralezijska uporaba
Intralesional use Intralesional use
intralezijska uporaba
Intralesional use only
samo za intralezijsko uporabo
Intralesional use.
intralezijska uporaba
Intramammary solution
Intramamarna raztopina.
Intramammary use
Intramamarna uporaba.
Intramuscular
Intramuskul arna uporaba
Intramuscular
intramuskularna
Intramuscular
uporaba intramuskularna
Intramuscular (IM) and subcutaneous (SC) use
intramuskularna (i.m.) in subkutana (s.c.) uporaba
Intramuscular (IM) and subcutaneous (SC) use.
intramuskularna (i.m.) in subkutana (s.c.) uporaba
Intramuscular (IM) use.
Intramuskularna (i.m.) uporaba.
Intramuscular (IM) use.
intramuskularna uporaba
Intramuscular dosing at 40 mcg/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Intramuskularno dajanje v odmerku 40 mcg/kg (ki mu sledi ketamin ali propofol) je pogosto imelo za posledice sinusno bradikardijo in sinusno aritmijo, občasno izraženo v prvi stopnji atrioventikularnega bloka ter redko supraventrikularno prezgodnjo depolarizacijo, atrijsko bigemijo, sinusni premor, drugo stopnjo atrioventrikularnega bloka ali manjkajoč utrip/ritem.
Intramuscular dosing at 40 micrograms/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Intramuskularno dajanje v odmerku 40 mikrogramov/kg (ki mu sledi ketamin ali propofol) je pogosto povzročilo sinusno bradikardijo in sinusno aritmijo, občasno izraženo v prvi stopnji atrioventrikularnega bloka ter redko supraventrikularno prezgodnjo depolarizacijo, atrijsko bigemijo, sinusni premor, drugo stopnjo atrioventrikularnega bloka ali manjkajoč utrip/ritem.
Intramuscular dosing at 40 micrograms/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Intramuskularno dajanje v odmerku 40 mikrogramovg/kg (ki mu sledi ketamin ali propofol) je pogosto povzročilo sinusno bradikardijo in sinusno aritmijo, občasno izraženo v prvi stopnji atrioventikularnega bloka, ter redko supraventrikularno prezgodnjo depolarizacijo, atrijsko bigemijo, sinusni premor, drugo stopnjo atrioventrikularnega bloka ali manjkajoč utrip/ritem.
Intramuscular haemorrhage (no compartment syndrome)
intramuskularna krvavitev (brez utesnitvenega sindroma)
intramuscular injection
intramuskularn a injekcija
Intramuscular injection
Intramuskularno dajanje
Intramuscular injection of 1 dose (2 ml) of vaccine per animal in the neck in the area behind the ear.
Intramuskularno dajanje 1 odmerka (2 ml) cepiva na žival v vrat v predel za ušesom.
Intramuscular injection only.
Samo za intramuskularno injiciranje.
Intramuscular injection.
Intramuskularno injiciranje.
Intramuscular or subcutaneous
intramuskularno
Intramuscular or subcutaneous injection of 0.25 or 0.5 ml, depending on the age.
Intramuskularno ali subkutano odmerek po 0,25 ali 0,5 ml, glede na starost.
Intramuscular or subcutaneous use (0.25 to 0.5 ml, depending on the age).
Intramuskularna ali subkutana uporaba (0,25 do 0,5 ml, odvisno od starosti).
Intramuscular or subcutaneous use.
Intramuskularna ali subkutana uporaba.
Intramuscular use
Intramusk
Intramuscular use
Intramusku larna uporaba
Intramuscular use
Intramuskula rno
Intramuscular use
Intramuskularn a uporaba
Intramuscular use
intramuskularna
Intramuscular use
Intramuskularna uporaba Intramuskularna uporaba
Intramuscular use
Intramuskularna uporaba.
Intramuscular use
Intramuskularno dajanje.
Intramuscular use
Intramuskularno uporabo
Intramuscular use
MESECE
Intramuscular use
NAVODILA ZA UPORABO
Intramuscular use
Način uporabe
intramuscular use
promet
intramuscular use
uporaba
Intramuscular use
uporaba Intramuskularna
Intramuscular use
uporabo
Intramuscular use
za intramuskularno
Intramuscular use
za intramuskularno uporabo
Intramuscular use only.
Samo za intramuskularno uporabo.
Intramuscular use powder: vial (glass);
prašek: viala
Intramuscular use pre-filled syringe (glass)
Intramuskularna
Intramuscular use Shake before use
intramuskularna uporaba Pred uporabo pretresite.
intramuscular use Shake well before use
Intramuskularna uporaba Pred uporabo dobro pretresite
Intramuscular use Shake well before use
Intramuskularna uporaba Pred uporabo pretresite
Intramuscular use Vaccination schedule:
Intramuskularna uporaba Shema cepljenja:
Intramuscular use Vaccination schedule:
Intramuskularno Shema cepljenja:
Intramuscular use, intravenous use, subcutaneous use
Intramuskularna uporaba Intravenska uporaba Subkutana uporaba
Intramuscular use, Intravenous use, Subcutaneous use
Intramuskularna, intravenska ali subkutana uporaba
Intramuscular use, subcutaneous use
Intramuskularna uporaba Subkutana uporaba
Intramuscular use.
Intramuskularno dajanje
Intramuscular use.
tirotropin alfa intramuskularna uporaba
Intramuscular use.
Za intramuskularno uporabo
Intramuscular use:
Intramuskularna uporaba.
INTRANASAL SPRAY/DEVICE LABEL
PRŠILO ZA NOS/NALEPKA NA PRŠILNIKU
Intranasal use
Nazalna uporaba
Intranasal/ocular, spray or drinking water
Intranazalno/okularno, razprševanje ali v vodi za pitje
Intraocular haemorrhage
intraokularna krvavitev
Intraocular haemorrhage
znotrajočesna krvavitev
Intraocular pressure increased
zvišan intraokularni tlak
Intraocular pressure increased, cataract, conjunctival haemorrhage*
Zvišan očesni tlak, katarakta, krvavitev očesne veznice
Intraocular use
intraokularna uporaba
Intraoperative Floppy Iris Syndrome
medoperacijs ki sindrom ohlapne šarenice
Intraoperative Floppy Iris Syndrome
Sindrom ohlapne šarenice
Intraoperative Floppy Iris Syndrome (IFIS)
Medoperacijski sindrom ohlapne šarenice (IFIS)
Intraoperative floppy iris syndrome (IFIS) has been observed during cataract surgery in patients treated with medicinal products with alpha1a-adrenergic antagonist effect, such as Xeplion (see section 4.8).
Pri bolnikih, zdravljenih z zdravili z antagonističnim učinkom na receptorje alfa-1a, kakršno je tudi zdravilo Xeplion (glejte poglavje 4.8), so med operacijo sive mrene opazili sindrom ohlapne šarenice (IFIS).
Intraoperative Floppy Iris Syndrome (IFIS):
Medoperacijski sindrom ohlapne šarenice (IFIS)
Intraoperative pupil diameter (mm) change-from-baseline
Sprememba premera zenice (mm) med operacijo glede na izhodišče
Intraosseous use
Intaosalna uporaba
Intraosseous use
intraosalna uporaba
Intraosseous use.
intraosalna uporaba
Intraperitoneal (IP) use
Intraperitonealna (i.p.) uporaba
Intraperitoneal use
Intraperitonealna uporaba
Intraperitoneal use Intraperitoneal use
intraperitonalna uporaba
Intraruminal device:
Intraruminalni sistem:
Intraruminal use
Intraruminalna uporaba
Intrathecal
intratekalno
Intrathecal administration of cytarabine may cause myelopathy (3%) and other neurologic toxicities sometimes leading to a permanent neurological deficit.
Intratekalno dajanje citarabina lahko povzroči mielopatijo (3%) in druge nevrotoksične učinke, ki občasno pripeljejo do trajne nevrološke okvare.
Intrathecal co-administration of cytarabine with other cytotoxic agents may increase the risk of neurotoxicity.
Skupna intratekalna uporaba citarabina in drugih citotoksičnih učinkovin lahko poveča tveganje nevrotoksičnih učinkov.
Intrathecal treatment of lymphomatous meningitis.
Intratekalno zdravljenje limfomatoznega meningitisa.
Intrathecal use
Intratekalna uporaba
Intrathecal use
Intratekalna uporaba.
Intrathecal use.
intratekalna uporaba
Intrauterine device (IUD)
vazektomija maternični vložek (IUD)
Intrauterine device (IUD).
vazektomija in intrauterini vložek (IUV).
Intrauterine foetal death
intrauterino odmrtje ploda,
Intravascular administration is contraindicated and may cause thromboembolism.
Intravaskularna uporaba je kontraindicirana in lahko povzroči tromboembolijo.
Intravascular administration of iodinated contrast agents (see section 4.4)
intravenski uporabi jodiranih kontrastnih sredstev (glejte poglavje 4.4); dojenju.
intravascular administration of iodinated contrast agents (see section 4.4) lactation.
intravaskularna uporaba jodiranih kontrastnih sredstev (glejte poglavje 4.4); dojenju.
intravascular administration of iodinated contrast agents (see section 4.4);
intravaskularna uporaba jodiranih kontrastnih sredstev (glejte poglavje 4.4);
Intravascular administration of iodinated contrast agents in radiological studies may lead to renal failure, resulting in metformin accumulation and risk of lactic acidosis.
Intravenska uporaba jodiranih kontrastnih sredstev v radioloških študijah lahko povzroči odpoved ledvic, posledično kopičenje metformina in tveganje za laktacidozo.
Intravascular administration of iodinated contrast media may lead to renal failure, resulting in metformin accumulation with the risk of lactic acidosis.
Intravaskularna aplikacija jodiranih kontrastnih sredstev lahko povzroči odpoved ledvic, kar povzroči kopičenje metformina s tveganjem za laktacidozo.
Intravenous
Intravenska
Intravenous
intravensko
Intravenous (80 micrograms/kg/day) administration of filgrastim to rabbits during the period of organogenesis was maternally toxic and increased spontaneous abortion, post-implantation loss, and decreased mean live litter size and fetal weight were observed.
Intravensko (80 mikrogramov/kg/dan) dajanje filgrastima kuncem v obdobju organogeneze je bilo toksično za mater, opazili so povečano število spontanih splavov, pogostejšo izgubo zarodka po implantaciji in zmanjšano velikost in maso ploda.
Intravenous (bolus) injection for acute STEMI indication only
Intravensko (bolusno) injiciranje – samo za indikacijo akutni STEMI
Intravenous (bolus) injection for acute STEMI indication only: Inhixa may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose in water.
Intravensko (bolusno) injiciranje – samo za indikacijo akutni STEMI: Zdravilo Inhixa se lahko varno uporablja z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje ali 5-odstotno glukozo v vodi.
Intravenous (bolus) injection for acute STEMI indication only: Thorinane may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose in water.
Intravensko (bolusno) injiciranje – samo za indikacijo akutni STEMI: Zdravilo Thorinane se lahko varno uporablja z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje ali 5-odstotno glukozo v vodi.